39 results about "Uterine fibroids" patented technology

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

The invention discloses a uterine fibroid recognition method based on artificial intelligence. The method comprises the following steps of S1, collecting medical image data of a tested person; s2, preprocessing the medical image data; s3, inputting the preprocessed data into a uterine fibroid deep learning model based on artificial intelligence to extract uterine fibroid features; wherein the deep learning model comprises a feature extraction layer, the feature extraction layer adopts a structure comprising a convolutional layer and jump connection, and the jump connection can select different processing modes according to an obtained input feature map and channel number so as to facilitate information transmission and gradient propagation; and S4, inputting the hysteromyoma features into a classification layer to obtain a hysteromyoma recognition result. According to the invention, aiming at the magnetic resonance medical image, a data processing and deep learning method is improved, and the accuracy and reliability of hysteromyoma identification are further improved.

The invention provides a 3D U-Net-based hysteromyoma intelligent measurement and evaluation system, and the system comprises an intelligent recognition module which is used for constructing a 3D U-Net network model, inputting a real-time image into the 3D U-Net network model for myoma boundary recognition, and judging whether a patient suffers from hysteromyoma or not; the three-dimensional reconstruction module is used for performing three-dimensional reconstruction on the real-time image when the judgment result is that the patient suffers from the hysteromyoma; the growth prediction module is used for performing uterine fibroid growth prediction according to the three-dimensional reconstruction result and outputting a growth prediction result; and the three-dimensional relationship between the myoma and the uterine muscular layer, the blood vessel and other organs can be observed more clearly, so that a more accurate basis is provided for formulating a personalized treatment scheme.

The invention discloses an application of a DHA-RXR-PPAR signal channel in promotion of postoperative recovery of hysteromyoma after HIFU (high intensity focused ultrasound). Clinical sample metabolic spectrum analysis and in-vitro cell function experiments are combined, and research proves that the differential metabolite DHA drives macrophage metabolism reprogramming through an RXR-PPAR signal axis, so that the macrophage is promoted to be transformed into an anti-inflammatory and phagocytosis-promoting repair phenotype, the absorption and repair process of the HIFU postoperative hysteromyoma is accelerated, and the treatment effect of the HIFU postoperative hysteromyoma is improved. A new intervention target spot (RXR-PPAR gamma axis) and a new potential medicine are provided for HIFU (high intensity focused ultrasound) postoperative rehabilitation.

The sustained-release formulation of this invention, with its increased initial release, exhibits a rapid release effect within 24 hours after administration, followed by a sustained-release effect, thus simultaneously achieving both prolonged efficacy and rapid initial release. The sustained-release formulation of this invention, containing microspheres of leuprorelin, possesses excellent bioavailability and has been proven safe in humans; therefore, it can be effectively and safely used to treat various luteinizing hormone-releasing hormone-related diseases such as endometriosis, uterine fibroids, prostate cancer, premenopausal breast cancer, and central precocious puberty.

The invention belongs to the field of medical instruments, and particularly discloses a gradient dentition-based hysteromyoma rotary cutter which comprises a rotary cutter bar, the rotary cutter bar is of a hollow tubular structure, a conveying cavity is formed in the rotary cutter bar in a penetrating mode in the axis direction of the rotary cutter bar, a gradient dentition structure is arranged on the inner wall of the front end of the conveying cavity, and the gradient dentition structure is arranged in the axis direction of the conveying cavity; the pull rod is arranged to pull the hysteromyoma slice to promote the hysteromyoma slice to be conveyed to the rear end of the conveying cavity when the rotary cutter bar rotates; the rotary cutter head is fixedly connected to the front end of the rotary cutter bar and is used for cutting hysteromyoma; and a rotary cutting driving device is arranged in the operating handle, is in transmission connection with the rear end of the rotary cutter bar, and is configured to drive the rotary cutter bar to rotate by taking the axis of the rotary cutter bar as a rotating shaft. By means of the structural design, the rotary cutter can pull cut hysteromyoma slices to be conveyed backwards, continuity and high efficiency of an operation are ensured, and meanwhile diffusion of tissue fragments in an operation area is prevented.

The invention discloses a method for classifying hysteromyoma and hysterosarcoma by using MRI (Magnetic Resonance Imaging) imageomics, which comprises the following steps of: acquiring MRI original image data of two types of patients with lesions through a three-dimensional image processing workstation, and extracting feature data; inputting the image data into an MRI image perception graph convolutional network, dynamically adjusting and extracting features through a multi-scale convolution kernel, and generating an initial image feature graph; inputting the initial feature map into a generative adversarial feature unwrapping network, and separating calibration features and interference features through adversarial training of a generator and a discriminator; the calibration features are input into a multi-instance learning attention model, lesion area feature representation is enhanced through a weight distribution mechanism, and weighted features are obtained; and constructing a lesion classification feature set in combination with MRI image omics features, and outputting a classification result by a classifier according to the optimized feature set. According to the method, the feature quality is cooperatively improved through a multi-link technology, the classification accuracy and objectivity are guaranteed, subjective interference is reduced, different MRI image characteristics are adapted, and clinical precise classification requirements can be met.

The present invention relates to a nitrogen-containing heteropolycyclic derivative modulator, a preparation method therefor and the use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as a modulator in the preparation of drugs for treating menopausal syndrome, polycystic ovarian syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related disorders thereof, wherein each substituent in general formula (I) is the same as defined in the description.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

Embodiments of the present application disclose an ultrasound image registration method, device and electronic equipment, the method comprising the following steps: acquiring an abdominal ultrasound image of a patient as a floating image, and extracting a uterine fibroid contour in the floating image based on a trained network model; acquiring a corresponding abdominal gray-scale ultrasound as a reference image, and labeling an upper boundary of the uterine fibroid to obtain an incomplete contour; fitting the obtained complete and incomplete uterine fibroid contours into regular geometric contours; describing the regular geometric contours using a point set shape description method, and matching regular elliptical contours in the regular geometric contours to regular elliptical arc contours according to a shape difference matching rule; and describing the initial complete and incomplete uterine fibroid contours using the point set shape description method, matching the point sets of the initial complete and incomplete uterine fibroid contours according to the shape difference, and obtaining a transformation matrix to perform fine registration.

This application relates to the field of automated gynecological disease technology, specifically a method and system for predicting the risk of uterine fibroids. By combining multiple sets of clinical indicators and multiple sets of imaging feature data, this application can effectively assess and predict the preoperative risk of uterine fibroids, especially for high-intensity focused ultrasound ablation. This scoring data provides a more intuitive determination of preoperative risk, thereby achieving an accurate assessment of the preoperative risk of uterine fibroids. Compared to existing technologies that rely solely on physician clinical experience, this application combines imaging feature data with clinical indicators, resulting in a more accurate assessment.

The application discloses a uterus tumor differential diagnosis method and system based on multi-parameter MRI imaging and belongs to the technical field of medical image processing and artificial intelligence diagnosis. The method aims at the problems existing in the current uterus tumor MRI diagnosis, such as strong subjective dependence, insufficient utilization of multi-parameter information, unreasonable feature screening and model construction. The method comprises the following steps: collecting T1WI, T2WI, T2 fat suppression sequence and DWI multi-parameter images; after format standardization, deartifacting and Z-score normalization, a model combining U-Net and attention mechanism is used to realize automatic segmentation of the lesions; multi-dimensional features are extracted and the optimal subset is screened by ANOVA filtering-RFE-SVM packaging method; a stacking integrated model is constructed for training, and the output includes the differential results and confidence of ordinary uterine fibroids, special type uterine fibroids and uterine sarcoma; the application integrates multi-parameter complementary information, improves the segmentation efficiency and feature quality, has strong model generalization ability and accurate diagnosis, is suitable for the actual situation of the scarcity of uterine sarcoma cases, and provides an objective diagnosis tool for clinical use.

In aspects, the present disclosure provides a method of treating or preventing a uterine fibroid in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of an inhibitor of bromodomain (BRD) protein.

This invention relates to the field of biometric recognition software and image pattern analysis technology, and discloses an automatic extraction method for preoperative image features of uterine fibroids using focused ultrasound ablation for re-pregnancy assessment. The method includes: acquiring image voxel data of the target entity and calculating its geometric center; traversing candidate anchor points in a three-dimensional neighborhood space and identifying gradient maxima to determine the optimal sampling origin; emitting a spatial sampling vector from the optimal sampling origin to establish a radial sampling field; calculating the gradient and energy characteristics at interface attribute transitions; and fusing them after noise component stripping to generate a descriptor vector. This invention utilizes dynamic optimization of the sampling origin to achieve orthogonal alignment between the sampling path and the tissue interface, suppressing non-pathological diffusion of signal steps at the mechanistic level, and improving the accuracy and uniqueness of biometric descriptors in representing the physical integrity of tissues.

The present invention relates to benzothiophene derivatives modulators, processes for their preparation and use. In particular, the present invention relates to compounds of general formula (I), processes for their preparation, pharmaceutical compositions containing them and their use as modulators in the preparation of medicaments for the treatment of menopausal symptoms, polycystic ovary syndrome, uterine fibroids, schizophrenia, irritable bowel syndrome, vasomotor symptoms, breast cancer and related conditions, wherein the substituents of general formula (I) are as defined in the description.

The invention provides a hysteromyoma segmentation and prognosis analysis method based on a diffusion model. The method comprises the following steps: collecting and preprocessing 3D T2 MRI image data of a hysteromyoma patient, and converting original data into data available for a machine; then, designing a uterine fibroid segmentation model in the 3D MRI image based on a diffusion model, and designing a function combining Dice loss, binary cross entropy loss and position loss to optimize model parameters in a denoising process, thereby extracting key features of a focus area and proposing redundant features; and key features of the segmented image are further extracted by using a 3D-ResNet network and are used for prognosis analysis, so that accurate prediction of the HIFU curative effect is realized.

A hysteroscopic specimen collection device includes a connecting piece and a collection bag. The connecting piece has an operating through hole and a first adhesive layer on its back. The lower end of the connecting piece is connected to the opening side of the collection bag. A first filter and a second filter are installed sequentially from top to bottom inside the collection bag. The first filter is detachably installed inside the collection bag. The diameter of some filter holes in the second filter is smaller than the diameter of some filter holes in the first filter. A fixing plate is provided on the back of the connecting piece or the collection bag to assist in fixing the collection device during use. The first and second filters of this invention facilitate the separation of tissue specimens and distension fluid flowing into the collection bag, enabling specimen collection and separation of specimens of different sizes, such as easily separating uterine fibroid tissue and endometrial tissue. The first adhesive layer and the fixing plate together fix the collection device. The overall structure is simple, convenient, and practical.

1. Name of the product in this design: Wireless Portable Back Fat Measuring Ultrasonic Instrument. 2. Application of this design: Combining the functions of a uterine lifter and intrauterine ultrasound, this product serves as both a uterine lifter and provides ultrasound localization for fibroids in minimally invasive uterine fibroid surgery. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The invention discloses a tanshinone I intrauterine sustained-release medicament for treating gynecological tumors and application thereof, which is characterized in that tanshinone I is prepared into a nano-structure lipid carrier with the average particle size of 100-200nm, so that the water solubility and biological membrane permeability of the nano-structure lipid carrier are remarkably improved; and then the carrier is loaded in a biodegradable polymer slow-release rod which can be placed in a uterine cavity. The sustained-release rod can release drugs when the environment in the uterine cavity declines, and local, long-acting and targeted drug delivery to the focus part is achieved. An in-vitro cell experiment proves that the inhibiting effect of the preparation on hysteromyoma cells is obviously higher than the toxicity of the preparation on normal hysteromyoma cells, and the selectivity index is greater than 2; therefore, the problems of poor solubility of tanshinone I and weak systemic administration targeting are solved, and the tanshinone I has the outstanding advantages of high efficiency, low toxicity and good patient compliance.

The invention relates to compositions and methods for treating uterine fibroids, wherein a uterine fibroid treatment agent comprising collagenase in an amount effective to cause shrinkage of uterine fibroids is injected or inserted into the uterine fibroid.

The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists.

This invention discloses a pharmaceutical composition for treating uterine fibroids, its preparation method, and its application, relating to the field of traditional Chinese medicine technology. The drug of this invention has the effects of softening and dispersing masses, breaking up lumps and eliminating masses, detoxifying and relieving pain, moistening dryness and promoting blood circulation, and regulating qi and dispersing blood stasis. It is composed of the following traditional Chinese medicine raw materials: *Deer antler cap*, *Da Jiu Jia*, fennel, *Spatholobus suberectus*, *Xue Tong*, *Evodia rutaecarpa*, *Aconite*, *Angelica sinensis*, *Ligusticum chuanxiong*, *Cyperus rotundus*, *Saussurea costus*, *Smilax china*, peach kernel, safflower, leech, earthworm, *Eupolyphaga sinensis*, cinnamon twig, and *Achyranthes bidentata*. The dosage form of the drug for treating uterine fibroids is a powder. Patients take 20-30 grams of the drug orally three times a day, mixed with 15-20 grams of honey in 275 ml of drinking water. The application refers to the use of the above-mentioned pharmaceutical composition and preparation in the preparation of drugs for treating or preventing uterine fibroids. The traditional Chinese medicine composition provided by this invention has significant efficacy in treating uterine fibroids, is non-toxic, has no side effects, has a reasonable formula, is simple to prepare, and has a low cost.

The application belongs to the field of medicine, and particularly relates to application of naringenin in preparation of medicines for treating uterine fibroids or uterine sarcoma. It is found through exploration that naringenin has obvious inhibitory effect on extracellular matrix synthesis of human primary uterine fibroid cells hUL and rat uterine fibroid cell line ELT-3, thereby inhibiting cell proliferation and migration; meanwhile, naringenin can significantly inhibit expression of cell cycle related enzymes of human uterine sarcoma cell lines SKN, SKUT-1 and MES-SA, thereby inhibiting cell proliferation and promoting cell apoptosis. The application lays a research foundation for exploring medicines for treating uterine fibroids or uterine sarcoma.

This invention relates to a method and system for predicting fertility in patients with uterine fibroids, comprising: identifying target clinical multimodal data; constructing a training set and an internal validation set based on the target clinical multimodal data; performing feature selection based on the training set, wherein univariate significance analysis is first performed, then clustering is performed based on a combination of variance inflation factor and maximum information coefficient, and finally feature grouping and representative features are selected based on a correlation graph; the target feature set and internal validation set after feature selection are input into a two-layer ensemble learning model for model training, wherein the base learner layer of the model includes multiple base models, and the meta-learner layer selects a support vector machine as the meta-learner; during training, a meta-feature matrix is ​​constructed based on the output values ​​of each base model, and the meta-feature matrix is ​​input into the meta-learner, which dynamically compensates for the prediction bias of each base model; and fertility prediction for uterine fibroids is performed based on the trained model.

The application discloses a uterine fibroid tissue interface 3D model and a manufacturing method and a phased transducer focal region form regulation system, the method first acquires a uterine fibroid MRI image of a patient; then the MRI image is processed to obtain a two-dimensional image data with contour marking; and a three-dimensional modeling with marking information is constructed; finally, according to the three-dimensional model, a material similar to biological tissue in acoustic characteristics is selected to obtain the 3D model through 3D printing. The 3D uterine fibroid tissue interface model can accurately reflect the boundary interface shape and acoustic impedance difference between different biological tissues. Through this model, the focal region form can be more effectively regulated, thereby improving the precision and treatment effect of HIFU in treating uterine fibroids. The model integrates multi-dimensional information of tissue thickness, acoustic impedance characteristics and their interaction, and provides important support for preclinical verification of medical devices and development of personalized treatment plans.

Disclosed herein are methods of treating uterine leiomyomas in a subject in need thereof comprising administering a STAT3 pathway inhibitor to the subject, methods of killing a tumor cell comprising contacting the tumor cell with a STAT3 pathway inhibitor, and methods of reducing the likelihood of recurrence of uterine leiomyomas in a subject in need thereof comprising administering a STAT3 pathway inhibitor.

The utility model provides a hysteromyoma extraction device for gynaecology and obstetrics operation, which belongs to the technical field of medical instruments and comprises grasping forceps, an excision knife tube, a puncture cannula, a protective sleeve and an electric handle, the non-driving end of the electric handle is connected with the puncture cannula, the driving end of the electric handle is connected with the excision knife tube, the puncture cannula is sleeved on the outer side of the excision knife tube, and the protective sleeve is sleeved on the outer side of the puncture cannula. The grasping end of the grasping forceps penetrates through a pipe of the cutting knife pipe, the grasping end of the grasping forceps is sleeved with the protective sleeve, the grasping forceps comprise a forceps head, a forceps pipe, a spring handle, a supporting body and a one-way switch piece, the two ends of the forceps pipe are connected with the forceps head and the spring handle respectively, the spring handle controls opening and closing of the forceps head through a pull rod, and the supporting body and the one-way switch piece are connected into the forceps pipe. The supporting body is connected with the one-way switch piece, and a flushing connector is arranged on the forceps tube. When the grasping forceps enter the body of a patient, a buffering effect can be achieved, tissues around the uterus are prevented from being damaged, blood is effectively prevented from entering a forceps tube, and the grasping forceps are convenient to clean.

The utility model relates to a radio frequency ablation electrode and an ablation electrode system, and belongs to the technical field of medical instruments. The ablation electrode system comprises a radio frequency host foot switch and a radio frequency ablation electrode, the radio frequency ablation electrode comprises an outer electrode and an inner electrode which are insulated from each other, the inner electrode is arranged in the outer electrode in a penetrating mode, and the front end of the inner electrode comprises a needle-shaped central electrode tip and at least two lateral electrode tips which can be unfolded towards the two sides or folded inwards. The radiofrequency ablation electrode and the ablation electrode system can be used in cooperation with ultrasonic detection equipment, the radiofrequency ablation electrode can penetrate into hysteromyoma, the front end of the inner electrode is unfolded in the hysteromyoma to be distributed in a plane, a plane-shaped ablation area with a certain thickness or an ablation area similar to a water drop shape is formed, and the radiofrequency ablation electrode can penetrate into the hysteromyoma. The extension length of the front end of the inner electrode determines the size of a single ablation area, other parts of hysteromyoma can be ablated by manually rotating or moving the radiofrequency ablation electrode left and right, and the ablation range is controllable.